Global Amyloidosis Treatment Market Size, Share, Growth Analysis, By End-user(Hospitals, Clinics), By Treatment(Chemotherapy, Stem Cell Transplant)

Description

Global Amyloidosis Treatment Market size was valued at USD 5.46 billion in 2022 and is poised to grow from USD 5.87 billion in 2023 to USD 10.56 billion by 2031, at a CAGR of 7.6% during the forecast period (2024-2031).

Amyloidosis is the abnormal build-up of proteins called amyloids in different organs that may cause organ malfunction. Despite being an extremely uncommon ailment, the market for amyloidosis treatments is growing as a result of rising awareness and diagnostic rates. Popular treatments for amyloidosis include chemotherapy, stem cell transplantation, and targeted medicines such small molecule inhibitors and monoclonal antibodies. Future prospects for suppliers of amyloidosis treatments are also being generated by the global upsurge in spending in medical R&D. Future market growth for amyloidosis therapy might also be aided by increased attention on improving patient outcomes, growing healthcare spending, an aging population, and technological improvements in the medical field. The need for amyloidosis treatment is expected to increase over the course of the projected period due to a growing global need for early detection of the disease.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Amyloidosis Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Amyloidosis Treatment Market Segmental Analysis

The global amyloidosis treatment market can be segmented based on treatment type, end-user, and region. Based on treatment type, the market includes chemotherapy, stem cell transplant, symptomatic management, and novel therapies such as monoclonal antibodies and RNA-targeted therapies. End-users encompass hospitals, clinics, and research institutions. Geographically, the market can be divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Drivers of the Global Amyloidosis Treatment Market

Growing Prevalence of Amyloidosis: The need for amyloidosis therapy has grown due to an increase in the frequency of ATTR and AL amyloidosis worldwide. The burgeoning market for amyloidosis treatments is also being fueled by the expanding accessibility of sophisticated diagnostic techniques and rising public awareness of the disease.

Restraints in the Global Amyloidosis Treatment Market

Expensive therapy: Receiving therapy for amyloidosis can be expensive for patients, particularly if they want to use targeted medicines and other cutting-edge approaches. Long-term market growth for amyloidosis treatments is hampered by this increased cost burden.

Market Trends of the Global Amyloidosis Treatment Market

Developments in Targeted therapeutics: Research and development have made significant strides in the investigation and development of targeted therapeutics for amyloidosis. Small compounds and monoclonal antibodies were being extensively researched as possible therapies to prevent the disease's hallmark, the development or buildup of amyloid proteins. Several clinical trials were being conducted to assess the effectiveness and safety of these novel treatments.

Product Code: SQMIG35J2102

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Amyloidosis Treatment Market by End-user

Market Overview
Hospitals
Clinics
and Research Institutions

Global Amyloidosis Treatment Market by Treatment

Market Overview
Chemotherapy
Stem Cell Transplant
Symptomatic Management
and Novel Therapies

Global Amyloidosis Treatment Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alnylam Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ionis Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eidos Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Prothena Corporation plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akcea Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ionis Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncopeptides AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alexion Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (USA) [Acquired by Bristol-Myers Squibb]
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caelum Biosciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Spectrum Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EUSA Pharma (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

Global Amyloidosis Treatment Market Size, Share, Growth Analysis, By End-user(Hospitals, Clinics), By Treatment(Chemotherapy, Stem Cell Transplant) - Industry Forecast 2024-2031